Last reviewed · How we verify

NCT05090618

The Role of Genetic Factors in the Development of Myocardial Infarction in the Kazakh Population

Completed Last updated 14 March 2023
What this trial tests

trial testing DNA analysis in Heart Attack in 500 participants. Completed in 20 January 2023.

Timeline
23 October 2021
Primary endpoint
20 January 2023
20 January 2023

Quick facts

Lead sponsorAsfendiyarov Kazakh National Medical University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment500
Start date23 October 2021
Primary completion20 January 2023
Estimated completion20 January 2023
Sites1 location across Kazakhstan

Drugs / interventions tested

Conditions studied

Sponsor

Asfendiyarov Kazakh National Medical University

Who can join

Adults 18 to 60, any sex, with Heart Attack. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a GWAS study that aims to identify possible candidate genes associate to heart attack by exploring single nucleotide polymorphism (SNP) in a group of heart attack, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with heart attack

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of DNA analysis

Trials testing the same drug.

Other recruiting trials for Heart Attack

Currently open trials in the same condition.

Other Asfendiyarov Kazakh National Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05090618.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing